Astrotech Corporation

What they do

Astrotech Corporation (Nasdaq: ASTC) owns the Astrotech Mass Spectrometer Technology (AMS Technology) and an ATi gas chromatography column platform, which it licenses exclusively to wholly owned subsidiaries. 1st Detect makes the TRACER 1000 explosives and narcotics trace detector, which has held ECAC certification since 2019 and is deployed in approximately 37 locations in 16 countries as of March 31, 2026. AgLAB, Pro-Control, BreathTech and EN-SCAN target hemp/cannabis distillation, industrial process control, breath-based screening, and portable environmental GC-MS testing, respectively.

Revenue drivers

• 1st Detect (TRACER 1000 ETD/NTD) — The only product with commercial deployments, sold to airport, cargo and border security customers that accept ECAC certification; approved by TSA for the Air Cargo Security Technology List in June 2024 and in Stage II field trials.
• EN-SCAN — Portable, ruggedized environmental GC-MS for on-site testing of air, water and soil; the 10-Q MD&A cites the EN-SCAN Handheld GC alongside the TRACER 1000 as the products the company is transitioning toward commercial sale.
• AgLAB — Mass spectrometers for the hemp and cannabis market, initially focused on optimizing yields in distillation processes; development stage under its exclusive ATI license.
• Pro-Control and BreathTech — Pro-Control targets in-situ chemical process control for industrial manufacturing; BreathTech is developing a breath analysis tool for VOC metabolites. Both remain development-stage with no disclosed revenue.

Recent performance

Fiscal 2025 revenue was $1.0M, down from $1.7M in fiscal 2024, while annual net loss widened to $13.8M and operating cash flow was negative $13.0M. Quarterly revenue in fiscal 2026 was $171 thousand (June 2025), $297 thousand (September 2025), $148 thousand (December 2025) and $343 thousand (March 2026). In the third quarter of fiscal 2026, research and development expense was $554 thousand, down 28% from the prior-year quarter, as the company reported transitioning from development stage toward saleable products. At March 31, 2026, total assets were $16.2M, total liabilities $4.0M, shareholder equity $12.2M, and cash and equivalents $2.7M.

Strategy

Management states it is commercializing the AMS Technology through application-specific, wholly owned subsidiaries, each holding an exclusive license for its field of use. The company is introducing a line of ultra-portable, on-site, rugged environmental testing instruments using its ATi mass spectrometer and gas chromatography column technology, with simplified interfaces and automated calibration. In the most recent quarter it prioritized cost efficiency while investing selectively, and its sales team is described as advancing a pipeline across key markets. It is pursuing TSA checkpoint testing and continues Stage II field trials for air cargo, which if successful would add the TRACER 1000 to the qualified list.

Risks

• Recurring losses — Astrotech has incurred significant losses since inception and management states it anticipates continued losses for the foreseeable future, with a fiscal 2025 net loss of $13.8M.
• Development-stage revenue — The business units have earned limited revenue and management says it is uncertain whether they will earn revenue in the future or become profitable; fiscal 2025 revenue was only $1.0M.
• Capital needs — The company states it may need to raise additional capital to fund operations and commercialize its products, with cash and equivalents of $2.7M at March 31, 2026.
• Customer concentration — Astrotech discloses that it generates substantial revenue from a limited number of customers, so the loss of any such customer could harm results.

Outlook

Management says it will continue to balance rigorous expense control with strategic investments to convert pipeline opportunities into revenue growth, per CEO Thomas B. Pickens, III. It is transitioning from development stage toward saleable products for the EN-SCAN Handheld GC and 1st Detect TRACER 1000 lines. The pending outcome of TSA Stage II air cargo field trials and the checkpoint testing process are the stated regulatory milestones ahead. The 10-K risk factors continue to flag the possibility of raising additional capital.